Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDMDNASDAQ:ECORNASDAQ:PAVMNASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDMDBaird Medical Investment$6.45-9.2%$5.21$1.05▼$12.50$42.47M-0.9283,922 shs59,249 shsECORelectroCore$5.25+3.3%$5.74$4.47▼$19.49$38.96M0.7997,525 shs41,350 shsPAVMPAVmed$0.61-0.3%$0.68$0.55▼$1.90$10.43M1.06131,953 shs70,708 shsPYPDPolyPid$3.31-6.2%$2.90$2.30▼$4.49$33.73M1.25125,241 shs340,518 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDMDBaird Medical Investment-9.15%+48.28%+25.98%+14.77%+644,999,900.00%ECORelectroCore+3.35%-7.24%-0.94%-34.62%-9.01%PAVMPAVmed-0.26%-11.59%-3.14%-20.47%-34.05%PYPDPolyPid-6.23%-4.34%+17.79%+16.10%-19.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AN/AN/AECORelectroCore2.1266 of 5 stars3.52.00.00.00.62.50.6PAVMPAVmed4.0567 of 5 stars3.53.00.04.30.60.01.9PYPDPolyPid3.1317 of 5 stars3.65.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDMDBaird Medical Investment 0.00N/AN/AN/AECORelectroCore 3.00Buy$25.50385.71% UpsidePAVMPAVmed 3.00Buy$19.003,014.75% UpsidePYPDPolyPid 3.17Buy$11.80256.50% UpsideCurrent Analyst Ratings BreakdownLatest PAVM, ECOR, PYPD, and BDMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.006/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.006/5/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/2/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$11.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.504/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AN/AECORelectroCore$25.18M1.55N/AN/A$1.13 per share4.65PAVMPAVmed$2.99M3.49N/AN/A($0.92) per share-0.66PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDMDBaird Medical InvestmentN/AN/A0.00∞N/AN/AN/AN/AN/AECORelectroCore-$11.89M-$1.56N/AN/AN/A-46.24%-149.04%-61.24%8/6/2025 (Estimated)PAVMPAVmed$39.79M$0.710.86N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-1,069.37%-151.85%8/13/2025 (Estimated)Latest PAVM, ECOR, PYPD, and BDMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDMDBaird Medical InvestmentN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDMDBaird Medical InvestmentN/AN/AN/AECORelectroCoreN/A1.521.30PAVMPAVmedN/A0.370.37PYPDPolyPid4.430.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDMDBaird Medical Investment19.78%ECORelectroCore26.74%PAVMPAVmed19.93%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipBDMDBaird Medical Investment78.90%ECORelectroCore19.70%PAVMPAVmed7.30%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDMDBaird Medical InvestmentN/A6.58 million1.39 millionN/AECORelectroCore507.42 million5.96 millionNot OptionablePAVMPAVmed9017.09 million15.85 millionOptionablePYPDPolyPid8010.19 million7.67 millionNo DataPAVM, ECOR, PYPD, and BDMD HeadlinesRecent News About These CompaniesPolyPid (NASDAQ:PYPD) Price Target Lowered to $9.00 at Roth CapitalJune 19 at 2:58 AM | americanbankingnews.comPolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA ApprovalJune 18 at 5:43 PM | nasdaq.comPolyPid (NASDAQ:PYPD) Price Target Cut to $14.00 by Analysts at JMP SecuritiesJune 18 at 2:35 AM | americanbankingnews.comPolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsJune 16 at 7:20 PM | globenewswire.comFY2026 Earnings Estimate for PolyPid Issued By HC WainwrightJune 14, 2025 | americanbankingnews.comPESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection PreventionJune 11, 2025 | globenewswire.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met ...June 11, 2025 | seekingalpha.comCraig-Hallum Reaffirms Their Buy Rating on PolyPid (PYPD)June 11, 2025 | theglobeandmail.comPolyPid reports positive phase 3 surgical infection drug trialJune 11, 2025 | en.globes.co.ilNano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 TrialJune 11, 2025 | finance.yahoo.comPolyPid price target raised to $13 from $11 at H.C. WainwrightJune 11, 2025 | msn.comPolyPid (NASDAQ:PYPD) Price Target Raised to $13.00June 11, 2025 | americanbankingnews.comPolyPid shares surge on successful D-PLEX100 trial resultsJune 9, 2025 | in.investing.comBriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call TranscriptJune 9, 2025 | globenewswire.comPolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II TrialJune 9, 2025 | tipranks.comPolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary EndpointsJune 9, 2025 | globenewswire.comRoth Capital Estimates PolyPid's Q2 Earnings (NASDAQ:PYPD)June 9, 2025 | americanbankingnews.comPolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025June 8, 2025 | finance.yahoo.comPolyPid Ltd. to Host Conference Call on June 9 to Report Topline Data from SHIELD II Phase 3 Trial for D-PLEX100June 6, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Broadcom Earnings Preview: AVGO Stock Near Record HighsBy Leo Miller | June 3, 2025View Broadcom Earnings Preview: AVGO Stock Near Record Highse.l.f. Beauty Sees Record Surge After Earnings, Rhode DealBy Leo Miller | May 30, 2025View e.l.f. Beauty Sees Record Surge After Earnings, Rhode DealPAVM, ECOR, PYPD, and BDMD Company DescriptionsBaird Medical Investment NASDAQ:BDMD$6.45 -0.65 (-9.15%) As of 06/18/2025 03:59 PM EasternBaird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.electroCore NASDAQ:ECOR$5.25 +0.17 (+3.35%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.26 +0.01 (+0.19%) As of 06/18/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.PAVmed NASDAQ:PAVM$0.61 0.00 (-0.26%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.64 +0.03 (+4.92%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.PolyPid NASDAQ:PYPD$3.31 -0.22 (-6.23%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.42 +0.11 (+3.32%) As of 06/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
